Published in
American Association for the Advancement of Science, Science Translational Medicine, 414(9), 2017
DOI: 10.1126/scitranslmed.aao1690
Links
Tools
A precision therapy against cancers driven by KIT/PDGFRA mutations
Journal article published in 2017 by
Erica K. Evans 
,
Alexandra K. Gardino,
Joseph L. Kim ,
Brian L. Hodous ,
Adam Shutes,
Alison Davis ,
Xing Julia Zhu ,
Oleg Schmidt-Kittler ,
Doug Wilson,
Kevin Wilson,
Lucian DiPietro,
Yulian Zhang,
Natasja Brooijmans ,
Timothy P. LaBranche ,
Agnieszka Wozniak
and other authors.
,
Alexandra K. Gardino,
Joseph L. Kim ,
Brian L. Hodous ,
Adam Shutes,
Alison Davis ,
Xing Julia Zhu ,
Oleg Schmidt-Kittler ,
Doug Wilson,
Kevin Wilson,
Lucian DiPietro,
Yulian Zhang,
Natasja Brooijmans ,
Timothy P. LaBranche ,
Agnieszka Wozniak
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
BLU-285 is a selective and potent mutant KIT and PDGFRA inhibitor active in both preclinical and clinical settings.